Literature DB >> 6436203

Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma.

S J Buskirk, L L Gunderson, M A Adson, A Martinez, G R May, D C McIlrath, D M Nagorney, G K Edmundson, C E Bender, J K Martin.   

Abstract

Twenty patients with carcinoma of the gallbladder (GB-4 patients) or extrahepatic bile ducts (EHBD-16 patients) received radiation therapy with curative intent between January, 1980 and December, 1982. All 20 received 4500-5000 rad in 180-200 rad fractions to the tumor and regional lymph nodes. A 1000 to 1500 rad external beam boost was delivered in 180-200 rad fractions in 10 patients who received external beam alone or concomitant 5-Fluorouracil (5-FU). Three of the four GB and 5 of the 16 EHBD patients received a transcatheter boost with 192-Iridium (192Ir) to a dose of 2000-2500 rad calculated at a 0.5-0.1 cm radius. An additional 2 patients with EHBD lesions received an intraoperative electron (IORT) boost of 1500-2000 rad in one fraction calculated to the 90% isodose. Survival and patterns of failure were analyzed by site and treatment method. All four patients with GB carcinoma are dead of disease at 5 1/2, 6, 9 and 10 months from the date of diagnosis respectively. Three of the four developed diffuse peritoneal carcinomatosis. Five of the 16 patients with EHBD carcinoma are alive with a median follow-up of 18 months (range 6-23 months). Four of the 5 patients received a transcatheter 192Ir or IORT boost and all are without evidence of disease. Four of 9 patients who had a subtotal resection with transection of tumor, dilatation of the bile ducts with probes or curettement of the bile ducts developed either diffuse peritoneal carcinomatosis (3 patients) or a recurrence in the surgical scar (2 patients). Local failure was documented in 3 of the nine patients treated with external beam alone +/- 5-FU, and has been documented in one of the seven patients who received an IORT or transcatheter 192Ir boost. Further experience is necessary to determine whether this aggressive treatment will result in long-term disease-free survival in these patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436203     DOI: 10.1016/0360-3016(84)90198-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases.

Authors:  J C Flickinger; A H Epstein; S Iwatsuki; B I Carr; T E Starzl
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

2.  Antitumor effect of the paclitaxel-eluting membrane in a mouse model.

Authors:  Jin-Seok Park; Seok Jeong; Don Haeng Lee; Jin Hee Maeng; In Suh Park; Sangsoo Park
Journal:  Oncol Lett       Date:  2018-07-17       Impact factor: 2.967

3.  Internal radiation for bile duct cancer.

Authors:  W C Meyers; R S Jones
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

4.  The role of intraoperative radiation therapy in the treatment of bile duct cancer.

Authors:  Y Iwasaki; T Todoroki; K Fukao; K Ohara; T Okamura; A Nishimura
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

5.  Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital.

Authors:  Yi-Yin Jan; Chun-Nan Yeh; Ta-Sen Yeh; Tse-Ching Chen
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

6.  Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma.

Authors:  Yi-Yin Jan; Chun-Nan Yeh; Ta-Sen Yeh; Tsann-Long Hwang; Miin-Fu Chen
Journal:  World J Surg       Date:  2005-07       Impact factor: 3.352

7.  Adjuvant radiotherapy for gallbladder cancer: a dosimetric comparison of conformal radiotherapy and intensity-modulated radiotherapy.

Authors:  Xiao-Nan Sun; Qi Wang; Ben-Xing Gu; Yan-Hong Zhu; Jian-Bin Hu; Guo-Zhi Shi; Shu Zheng
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

8.  Radiotherapy of cholangiocarcinoma: the roles for primary and adjuvant therapies.

Authors:  T Shiina; S Mikuriya; T Uno; T Toita; S Serizawa; J Itami; S Kawai; M Tani
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Resection combined with intraoperative radiation therapy (IORT) for stage IV (TNM) gallbladder carcinoma.

Authors:  T Todoroki; Y Iwasaki; K Orii; M Otsuka; K Ohara; T Kawamoto; K Nakamura
Journal:  World J Surg       Date:  1991 May-Jun       Impact factor: 3.352

10.  Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience.

Authors:  R Schoenthaler; T L Phillips; J Castro; J T Efird; A Better; L W Way
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.